Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and outcomes. When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend. So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program.

Read our white paper